Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
APGE
APGE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
APGE News
Affinity Asset Advisors Increases Stake in Apogee Therapeutics
1d ago
Fool
Apogee Therapeutics (APGE.US) Officer Plans to Sell $3.84 Million in Common Stock via Form 144
4d ago
moomoo
Apogee Therapeutics (APGE) Options Volume Surges 46.6% Today
Jan 23 2026
NASDAQ.COM
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Jan 16 2026
Barron's
Apogee Therapeutics CMO Sells $1.46 Million in Shares
Jan 11 2026
NASDAQ.COM
Apogee Therapeutics CMO Sells $1.46 Million in Shares Following Options Exercise
Jan 11 2026
Fool
Apogee Therapeutics CMO Sells 10,900 Shares for $817,500
Jan 08 2026
Fool
APGE Options Offer 9.33% Yield Boost on $75 Put Contract
Jan 07 2026
NASDAQ.COM
Apogee Therapeutics Reports 60% FeNO Reduction in Phase 1b Trial of APG777 for Asthma
Jan 06 2026
Benzinga
Apogee Therapeutics Reports Positive Phase 1b Data for Zumilokibart in Asthma, Plans Phase 3 Trial in 2026
Jan 06 2026
NASDAQ.COM
Apogee Reports Positive Interim Results for APG777 in Asthma Trials
Jan 06 2026
Globenewswire
Apogee Therapeutics Reports Interim Phase 1b Results for APG777 in Asthma Today
Jan 06 2026
NASDAQ.COM
Amazon Analyst Starts Coverage Optimistically; Check Out Wednesday's Top 5 Initiations
Dec 10 2025
Benzinga
RBC Capital Reaffirms Outperform Rating for Apogee Therapeutics and Increases Price Target to $70
Nov 03 2025
Benzinga
Mizuho Begins Coverage of Apogee Therapeutics (APGE) with a Positive Outlook
Oct 22 2025
NASDAQ.COM
Mizuho Begins Coverage of Apogee Therapeutics with Outperform Rating and Sets Price Target at $105
Oct 21 2025
Benzinga
Show More News
